Strides Pharma Science Ltd reported robust Q1 FY2026 with Rs. 11,197 million revenue, Rs. 2,181 million EBITDA, and Rs. 1,140 million operational PAT, showing a 6.2% revenue growth year-on-year. This press release was made on July 29, 2025, highlighting a strong start to the fiscal year.